Anemia Study in chronic kidney disease (CKD) : Erythropoiesis via a Novel Prolyl hydroxylase inhibitor (PHI) Daprodustat –Forearm Blood Flow (ASCEND-FBF)

Trial Identifier: 205767
Sponsor: GlaxoSmithKline
Collaborator:
Not applicable
Start Date: January 2019
Primary Completion Date: May 2019
Study Completion Date: May 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United Kingdom Edinburgh, United Kingdom, EH16 4TJ
United Kingdom London, United Kingdom, SE1 7EH
United Kingdom, Cambridgeshire Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ